Peter Gibbs

Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group

Catherine Dunn, Wei Hong, Peter Gibbs, Stephen Ackland, Katrin Sjoquist, Niall C Tebbutt, Timothy Price, Matthew Burge

Journal article  |  2021  |  CLINICAL COLORECTAL CANCER

Palliative chemotherapy is the cornerstone of treatment for the majority of patients with metastatic colorectal cancer, with the a..

Neoadjuvant capecitabine in rectal cancer chemoradiotherapy: too early to ring the alarms reply

Matthew Loft, Hui-Li Wong, Peter Gibbs

Journal article  |  2021  |  INTERNAL MEDICINE JOURNAL

Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer

Matthew Loft, Hui-Li Wong, Suzanne Kosmider, Margaret Lee, Jeanne Tie, Rachel Wong, Ian T Jones, Matthew Croxford, Malcolm Steel, Ian Faragher, Mario Guerrieri, Michael Christie, Peter Gibbs

Journal article  |  2021  |  INTERNAL MEDICINE JOURNAL

BACKGROUND: Neoadjuvant chemoradiation therapy is standard-of-care treatment for locally advanced rectal cancer (LARC). A patholog..

Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.

Angelyn Anton, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Marie C Semira, Peter Gibbs, Ben Tran, Carmel Pezaro

Journal article  |  2021  |  Eur J Cancer

INTRODUCTION: Bone metastases occur frequently in castration-resistant prostate cancer (CRPC) and may lead to skeletal-related eve..

Genomic Risk Prediction for Breast Cancer in Older Women

Paul Lacaze, Andrew Bakshi, Moeen Riaz, Suzanne G Orchard, Jane Tiller, Johannes T Neumann, Prudence R Carr, Amit D Joshi, Yin Cao, Erica T Warner, Alisa Manning, Tu Nguyen-Dumont, Melissa C Southey, Roger L Milne, Leslie Ford, Robert Sebra, Eric Schadt, Lucy Gately, Peter Gibbs, Bryony A Thompson, et al.

Journal article  |  2021  |  CANCERS

Genomic risk prediction models for breast cancer (BC) have been predominantly developed with data from women aged 40-69 years. Pro..

Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?

Amanda Pereira-Salgado, Edmond Michael Kwan, Ben Tran, Peter Gibbs, Johann De Bono, Maarten IJzerman

Journal article  |  2021  |  EUROPEAN UROLOGY FOCUS

CONTEXT: Optimal treatment sequencing of abiraterone and enzalutamide in chemotherapy-naïve metastatic castration-resistant prosta..

Stage dependent recurrence patterns and post-recurrence outcomes in non-metastatic colon cancer

Lucy Gately, Azim Jalali, Christine Semira, Ian Faragher, Matthew Croxford, Sumitra Ananda, Suzanne Kosmider, Kathryn Field, Sheau Wen Lok, Grace Gard, Malcolm Steel, Margaret Lee, Rachel Wong, Hui-Li Wong, Peter Gibbs

Journal article  |  2021  |  ACTA ONCOLOGICA

BACKGROUND: Multiple meta-analyses have demonstrated that routine surveillance following colorectal cancer surgery improves surviv..

Treatment and Outcomes of Oligometastatic Colorectal Cancer Limited to Lymph Node Metastases.

Vinod Kalapurackal Mathai, Soe Yu Aung, Vanessa Wong, Catherine Dunn, Jeremy Shapiro, Azim Jalali, Rachel Wong, Margaret Lee, Jeanne Tie, Sumitra Ananda, Suzanne Kosmider, Stephanie H Lim, Susan Caird, Matthew Burge, Andrew Dean, Peter Gibbs, Louise Nott

Journal article  |  2021  |  Clin Colorectal Cancer

INTRODUCTION: The optimal management of isolated distant lymph node metastases (IDLNM) from a colorectal primary, is not clearly e..

Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?

Catherine Dunn, Lucy Gately, Peter Gibbs

Journal article  |  2021  |  JAMA ONCOLOGY

Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer

Yat Hang To, Koen Degeling, Suzanne Kosmider, Rachel Wong, Margaret Lee, Catherine Dunn, Grace Gard, Azim Jalali, Vanessa Wong, Maarten IJzerman, Peter Gibbs, Jeanne Tie

Journal article  |  2021  |  PHARMACOECONOMICS

BACKGROUND AND OBJECTIVE: Substantial adjuvant chemotherapy (AC) overtreatment for stage II colorectal cancer results in a health ..